2021-10-27T07:44:13-05:00 2020-12-31 861065772 DELOITTE TAX LLP 695 TOWN CENTER DRIVE SUITE 1000 COSTA MESA CA 92626 990 2020-01-01 980593375 GAVI ALLIANCE GAVI 2024781050 CHEMIN DU POMMIER 40 GRANDSACONNEX GENEVA SZ 1218 ASSIETOU DIOUF MANAGING DIR, FINANCE/OPER. 2024781050 2021-10-26 1 ASSIETOU DIOUF XXX-XX-XXXX JOHN W SADOFF JR P00540589 7144367100 3 AAL1 IAL1 2020 2022-09-23 18:48:47Z GAVI THE VACCINE ALLIANCE ASSIETOU DIOUF CHEMIN DU POMMIER 40 GRANDSACONNEX GENEVA SZ 1218 5428821167 0 X GAVI.ORG X 2009 SZ TO SAVE CHILDREN'S LIVES AND PROTECT PEOPLE'S HEALTH BY INCREASING EQUITABLE USE OF VACCINES IN LOWER-INCOME COUNTRIES. 46 46 23 57 0 0 800186577 2433703395 0 0 55335701 22864796 24373686 -125399918 879895964 2331168273 995854754 2014115924 0 0 53375707 57861874 0 0 18697238 51356179 44980640 1100586640 2116958438 -220690676 214209835 4241258942 6896842127 1071665879 3389804483 3169593063 3507037644 X TO SAVE CHILDREN'S LIVES AND PROTECT PEOPLE'S HEALTH BY INCREASING EQUITABLE USE OF VACCINES IN LOWER-INCOME COUNTRIES. 1 0 2068575735 2014115924 ACCELERATING EQUITABLE UPTAKE AND COVERAGE OF VACCINESCOUNTRIES IMMUNISED 64 MILLION UNIQUE CHILDREN WITH GAVI SUPPORT IN 2020. OF THIS NUMBER, EACH CHILD IS PROTECTED AGAINST APPROXIMATELY SEVEN INFECTIOUS DISEASE. TODAY, NEARLY FOUR IN FIVE CHILDREN IN GAVI-SUPPORTED COUNTRIES RECEIVE ROUTINE IMMUNISATION. DUE TO THE IMPACT OF THE COVID-19 PANDEMIC, COVERAGE WITH A FULL COURSE OF PENTAVALENT VACCINE AND THE FIRST DOSE OF MEASLES-CONTAINING VACCINE BOTH DECREASED TO 78% IN GAVI-SUPPORTED COUNTRIES, FROM 82% AND 81%, RESPECTIVELY A DECLINES LESS SEVERE THAN WHAT WAS FEARED.GAVI SUPPORTED 21 VACCINE INTRODUCTIONS AND CAMPAIGNS IN 2020, A DECREASE FROM 60 IN 2019 DUE TO THE IMPACT OF THE COVID-19 PANDEMIC.IN 2020, EMERGENCY STOCKPILES FOR CHOLERA, MENINGOCOCCAL AND YELLOW FEVER VACCINES WERE ACCESSED A TOTAL OF 11 TIMES BY 9 COUNTRIES.INCREASING THE EFFECTIVENESS AND EFFICIENCY OF IMMUNISATION DELIVERY AS AN INTEGRATED PART OF STRENGTHENED HEALTH SYSTEMSWHERE AVAILABLE, MONTHLY ADMINISTRATION DATA SUGGESTS THAT DESPITE A 40% REDUCTION IN IMMUNISATION ACTIVITY DURING THE FIRST WAVE OF THE COVID-19 PANDEMIC IN APRIL AND MAY 2020, ROUTINE IMMUNISATION BOUNCED BACK: BY DECEMBER 2020, MONTHLY IMMUNISATION RATES WERE ABOVE THOSE OF THE PREVIOUS YEAR.GAVI DISBURSED A RECORD OF US$ 383 MILLION IN HEALTH SYSTEM SUPPORT IN 2020. ANNUAL HEALTH SYSTEM STRENGTHENING (HSS) DISBURSEMENTS NEARLY DOUBLED OVER THE COURSE OF GAVI 4.0, TOTALLING US$ 1.42 BILLION FOR THE 2016-2020 STRATEGIC PERIOD COMPARED TO THE ORIGINAL BOARD-APPROVED ENVELOPE OF US$ 1.3 BILLION.THE TIME TAKEN TO DISBURSE CASH GRANTS TO COUNTRIES IMPROVED SIGNIFICANTLY, FROM 18 MONTHS IN 2018 TO AN AVERAGE OF SLIGHTLY UNDER 10 MONTHS IN 2020, WHICH IS CLOSER TO THE TARGET OF 9 MONTHS. WHEN INCLUDING GRANTS THAT WERE DELAYED BY AUDIT AND SUPPLY CONSTRAINTS, THE AVERAGE WAS 14 MONTHS.IMPROVING SUSTAINABILITY OF NATIONAL IMMUNISATION PROGRAMMESA TESTAMENT TO INCREASING COUNTRY OWNERSHIP AND THE LONG-TERM FINANCIAL SUSTAINABILITY OF GAVI-SUPPORTED VACCINES, 100% OF COUNTRIES PAID THEIR 2020 CO-FINANCING OBLIGATIONS ON TIME (EXCLUDING THE NINE COUNTRIES THAT RECEIVED AN EXCEPTIONAL WAIVER DUE TO THE COVID-19 PANDEMIC).BY THE END OF 2020, 88% OF COUNTRIES IN THE ACCELERATED TRANSITION PHASE WERE ON TRACK TO TRANSITION SUCCESSFULLY. THIS IS AN INCREASE FROM 67% IN 2019, EXCEEDING THE TARGET OF 75% BY 2020. THE ONLY COUNTRY THAT MISSED THE CRITERIA TO BE CONSIDERED ON TRACK FOR SUCCESSFUL TRANSITION DID SO BECAUSE OF ITS DTP3 COVERAGE LEVEL. THIS HIGHLIGHTS THE IMPORTANCE OF OUR PROGRAMMATIC SUSTAINABILITY WORK WITH COUNTRIES, WHICH WILL BE FURTHER EXPANDED IN GAVI 5.0. SHAPING MARKETS FOR VACCINES AND OTHER IMMUNISATION PRODUCTSIN 2020, THE WEIGHTED AVERAGE PRICE TO FULLY IMMUNISE A CHILD WITH PENTAVALENT, PNEUMOCOCCAL AND ROTAVIRUS VACCINES FELL TO US$ 15.20, A REDUCTION OF 24% SINCE 2015 AND A 2% DROP FROM THE PREVIOUS YEAR.BY THE END OF 2020, 10 OUT OF 11 VACCINE MARKETS WERE ASSESSED AS HAVING SUFFICIENT AND UNINTERRUPTED SUPPLY UP FROM 8 IN 2019. WHILE SUPPLY SECURITY FOR INACTIVATED POLIO VACCINE AND ORAL CHOLERA VACCINE WAS RE-ESTABLISHED, GLOBAL DEMAND FOR HUMAN PAPILLOMAVIRUS VACCINE CONTINUES TO OUTPACE AVAILABLE SUPPLY, DESPITE THE MANUFACTURING CAPACITY EXPANSION EFFORTS OF A MAJOR SUPPLIER TO GAVI.FURTHER INFORMATION ON GAVI'S PROGRESS TOWARDS ACHIEVING ITS STRATEGIC GOALS CAN BE FOUND IN ITS 2020 ANNUAL PROGRESS REPORT, ONLINE AT: HTTPS://WWW.GAVI.ORG/PROGRAMMES-IMPACT/OUR-IMPACT/PROGRESS-REPORTS. 2068575735 1 1 0 1 0 0 0 0 0 0 1 1 0 1 1 1 0 1 0 1 1 1 0 0 0 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 0 0 1 X 47 0 1 23 1 0 1 SZ NO EI 0 0 0 0 0 0 0 0 0 0 X 46 46 0 0 1 0 0 0 0 1 1 0 0 0 1 1 1 1 1 1 1 0 X ASSIETOU DIOUF 2024781050 CHEMIN DU POMMIER 40 GRANDSACONNEX GENEVA SZ 1218 X NGOZI OKONJO-IWEALA CHAIR 2.00 0.00 X 0 0 0 SARAH GOULDING VICE CHAIR - FROM 01/2020 2.00 0.00 X 0 0 0 OMAR ABDI BOARD MEMBER 2.00 0.00 X 0 0 0 BETH ARTHY BOARD MEMBER - FROM 09/2020 2.00 0.00 X 0 0 0 AFSANEH BESCHLOSS BOARD MEMBER - FROM 01/2020 2.00 0.00 X 0 0 0 ROGER CONNOR BOARD MEMBER - FROM 08/2020 2.00 0.00 X 0 0 0 MAHIMA DATLA BOARD MEMBER (ABM UNTIL 07/2020) 2.00 0.00 X 0 0 0 MATY DIA BOARD MEMBER 2.00 0.00 X 0 0 0 ABDOULAYE SABRE FADOUL BOARD MEMBER - FROM 09/2020 2.00 0.00 X 0 0 0 FEROZUDDIN FEROZ BOARD MEMBER - UNTIL 09/2020 2.00 0.00 X 0 0 0 DANIEL GRAYMORE BOARD MEMBER - UNTIL 09/2020 2.00 0.00 X 0 0 0 AMIR AMAN HAGOS BOARD MEMBER - UNTIL 07/2020 2.00 0.00 X 0 0 0 MARGARET PEGGY HAMBURG BOARD MEMBER 2.00 0.00 X 0 0 0 MYINT HTWE BOARD MEMBER 2.00 0.00 X 0 0 0 ZSUZANNA JAKAB BOARD MEMBER - FROM 03/2020 2.00 0.00 X 0 0 0 MAHAMOUD YOUSSOUF KHAYAL BOARD MEMBER - UNTIL 08/2020 2.00 0.00 X 0 0 0 ORIN LEVINE BOARD MEMBER 2.00 0.00 X 0 0 0 FRANCESCA MANNO BOARD MEMBER 2.00 0.00 X 0 0 0 MARTA NUNES BOARD MEMBER 2.00 0.00 X 0 0 0 AHMAD JAWAD OSMANI BOARD MEMBER - FROM 09/2020 2.00 0.00 X 0 0 0 JAN PAEHLER BOARD MEMBER (ABM UNTIL 01/2020) 2.00 0.00 X 0 0 0 MUHAMMAD PATE BOARD MEMBER 2.00 0.00 X 0 0 0 HARRIET PEDERSEN BOARD MEMBER 2.00 0.00 X 0 0 0 SAI PRASAD BOARD MEMBER - UNTIL 06/2020 2.00 0.00 X 0 0 0 HELEN REES BOARD MEMBER 2.00 0.00 X 0 0 0 TERESA RESSEL BOARD MEMBER 2.00 0.00 X 0 0 0 WILLIAM H ROEDY BOARD MEMBER 2.00 0.00 X 0 0 0 PETER SALAMA BOARD MEMBER - UNTIL 01/2020 2.00 0.00 X 0 0 0 DAVID SIDWELL BOARD MEMBER 2.00 0.00 X 0 0 0 SUSAN SILBERMAN BOARD MEMBER - UNTIL 07/2020 2.00 0.00 X 0 0 0 LIA TADESSE BOARD MEMBER - FROM 07/2020 2.00 0.00 X 0 0 0 ARSEN TOROSYAN BOARD MEMBER 2.00 0.00 X 0 0 0 YIBING WU BOARD MEMBER 2.00 0.00 X 0 0 0 STEPHEN ZINSER BOARD MEMBER 2.00 0.00 X 0 0 0 KWAKU AGYEMAN-MANU ALTERNATE BOARD MEMBER 2.00 0.00 X 0 0 0 EDNA YOLANI BATRES ALTERNATE BOARD MEMBER 2.00 0.00 X 0 0 0 MEGAN CAIN ALTERNATE BOARD MEMBER 2.00 0.00 X 0 0 0 SUSAN ELDEN ALTERNATE BOARD MEMBER 2.00 0.00 X 0 0 0 ASSAD HAFEEZ ALTERNATE BOARD MEMBER 2.00 0.00 X 0 0 0 ETLEVA KADILLI ALTERNATE BOARD MEMBER 2.00 0.00 X 0 0 0 NOOR KHAN ALTERNATE BOARD MEMBER - FROM 03/20 2.00 0.00 X 0 0 0 IRENE KOEK ALTERNATE BOARD MEMBER - UNTIL 06/20 2.00 0.00 X 0 0 0 LENE LOTHE ALTERNATE BOARD MEMBER - UNTIL 03/20 2.00 0.00 X 0 0 0 JACQUELINE LYDIA MIKOLO ALTERNATE BOARD MEMBER 2.00 0.00 X 0 0 0 VIOLAINE MITCHELL ALTERNATE BOARD MEMBER 2.00 0.00 X 0 0 0 KATE O'BRIEN ALTERNATE BOARD MEMBER - FROM 03/20 2.00 0.00 X 0 0 0 KEIICHI ONO ALTERNATE BOARD MEMBER - FROM 09/20 2.00 0.00 X 0 0 0 MICHAEL KENT RANSON ALTERNATE BOARD MEMBER 2.00 0.00 X 0 0 0 XIANG SHU ALTERNATE BOARD MEMBER - FROM 09/20 2.00 0.00 X 0 0 0 PRINCESS NOTHEMA SIMELELA ALTERNATE BOARD MEMBER - UNTIL 03/20 2.00 0.00 X 0 0 0 WILLIAM SCHLUTER ALTERNATE BOARD MEMBER 2.00 0.00 X 0 0 0 BOUNKONG SYHAVONG ALTERNATE BOARD MEMBER 2.00 0.00 X 0 0 0 TAMAKA TSUKADA ALTERNATE BOARD MEMBER - UNTIL 09/20 2.00 0.00 X 0 0 0 CARMEN COLES TULL ALTERNATE BOARD MEMBER - FROM 06/20 2.00 0.00 X 0 0 0 JOAN VALADOU ALTERNATE BOARD MEMBER - FROM 01/20 2.00 0.00 X 0 0 0 AN VERMEESCH ALTERNATE BOARD MEMBER 2.00 0.00 X 0 0 0 RAFAEL VILASANJUAN ALTERNATE BOARD MEMBER - FROM 03/20 2.00 0.00 X 0 0 0 DR SETH BERKLEY CHIEF EXECUTIVE OFFICER 47.50 2.50 X 649860 0 114672 ASSIETOU DIOUF MNG DIR, FIN & OPS. 47.50 2.50 X 225405 0 70451 PHILIP ARMSTRONG DIRECTOR, GOVERNANCE- UNTIL 07/2020 50.00 0.00 X 184128 0 44066 BRENDA KILLEN DIRECTOR, GOVERNANCE - AS OF 07/2020 44.00 6.00 X 167841 0 33158 ANURADHA GUPTA DEPUTY CHIEF EXECUTIVE OFFICER 48.50 1.50 X 350823 0 85852 PASCAL BAROLLIER MANAGING DIR, PUBLIC ENGAGEMENT 50.00 0.00 X 259656 0 81522 MARIE-ANGE SARAKA-YAO MANAGING DIR, RES MOBL./PARTNERSHIPS 50.00 0.00 X 265703 0 65071 THABANI MAPHOSA MANAGING DIR, COUNTRY PROGRAM 50.00 0.00 X 268660 0 61470 AURELIA NGUYEN OFFICE OF THE COVAX FACILITY 50.00 0.00 X 262206 0 67898 SIMON LAMB MNG DIR, AUDIT & INVESTIGATIONS 50.00 0.00 X 281919 0 72844 ELIZABETH DAVIES HEAD HUMAN RESOURCES 50.00 0.00 X 311792 0 39388 ALEX DE FAUQUE DE JONQUIERES DIR. HEALTH SYS. & IMMUNE. STRENGTH. 50.00 0.00 X 278106 0 63861 EDMUND GROVE DIRECTOR PROGRAMME AUDIT 50.00 0.00 X 271918 0 62244 ANDREW MENDS DIRECTOR OPERATIONS 50.00 0.00 X 270714 0 61916 4048731 0 924413 286 0 1 0 HELVETIC PAYROLL SA RUE DU LAUSANNE 44 GENEVA SZ TEMPORARY STAFFING 3406083 MCKINSEY AND COMPANY INC BLEICHERWEG 20 ZURICH SZ CONSULTING SERVICES 1850680 TECH MAHINDRA LIMITED OFF KARVE ROAD PUNE IN 411004 IT SERVICES 1664253 LINKLATERS LLP 1 ONE SILK STREET LONDON UK EC2Y 8HQ LEGAL SERVICES 666384 SAP SCHWEIZ AG LEUGENESTRASSE 6 BIEL SZ IT SERVICES 665981 94 210364608 1918382951 304955836 2433703395 16200090 16200090 3104299333 18267 3097652894 0 6646439 18267 6664706 6664706 OTHER INCOME 900099 27180 27180 FC TRANSLATION ADJ. 900099 -125427098 -125427098 -125399918 2331168273 0 0 -102535122 106426876 106426876 1907689048 1907689048 3258442 1897390 825364 535688 38214374 22251635 9678301 6284438 7646702 4452556 1936630 1257516 7948613 4628360 2013107 1307146 793743 462185 201028 130530 627478 627478 559977 559977 301200 141429 80152 79619 4957757 4957757 24281681 13055185 5040228 6186268 459779 70651 14597 374531 3281694 1956834 801445 523415 3117390 1953708 652231 511451 3608981 2151993 881373 575615 850566 520188 140251 190127 1160726 320549 259008 581169 698008 416214 170465 111329 303434 180934 74104 48396 TRAINING & RECRUITMENT 771969 771969 2116958438 2068575735 29685465 18697238 X 24780943 15518304 5201774 4060865 87205681 99277038 1411755626 3187411270 1475333817 1475819226 54225712 351028735 9990511 8052478 2354768 1938033 1136169765 1326662408 74213573 454705417 4241258942 6896842127 25772660 17946918 246809463 117860164 145215800 127112753 653867956 3126884648 1071665879 3389804483 X 2051335679 1643920333 1118257384 1863117311 3169593063 3507037644 4241258942 6896842127 X 214209835 107016869 16217877 X 0 1 X 1 0 X 1588607491 614655000 596158662 800186577 2433703395 6033311125 1588607491 614655000 596158662 800186577 2433703395 6033311125 695485156 5337825969 11971776 17988337 29223123 31105860 16200090 106489186 175353 542556 430236 274962 27180 1450287 6141250598 0.86920 0.74750 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: OTHER INCOME - 2016 AMOUNT: $ 47,926. 2017 AMOUNT: $ 407,132. 2018 AMOUNT: $ 295,261. 2019 AMOUNT: $ 266,165. 2020 AMOUNT: $ 27,180. PARKING FEES - 2016 AMOUNT: $ 127,427. 2017 AMOUNT: $ 135,424. 2018 AMOUNT: $ 134,975. 2019 AMOUNT: $ 8,797. 2020 AMOUNT: $ 0. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 0 0 0 0 0 0 1 301200 0 0 301200 0 PART II-B, LINE 1: FEES WERE PAID FOR: 1. PRESENTATION AND OUTREACH TO MEMBERS OF THE CONGRESS AND STAFF OF THE HOUSE AND SENATE COMMITTEES ON APPROPRIATIONS, AND ANY OTHER COMMITTEES NEEDED, TO REQUEST SUPPORT FOR THE GAVI ALLIANCE; AND 2. SUPPORT AND GUIDANCE TO GAVI ALLIANCE IN POSITIONING THE ORGANIZATION WITH THE ADMINISTRATION, AND OUTREACH TO MEMBERS OF THE CONGRESS AND STAFF ON VARIOUS COMMITTEES. 1185226 349413 835813 1219941 1122227 97714 7585344 6580838 1004506 1938033 LIMITED LIABILITY COMPANIES AND LIMITED PARTNERSHIPS 917501850 F REGISTERED INVESTMENT COMPANIES 409160558 F 1326662408 OTHER ASSETS 48093162 CURRENCY FORWARD CONTRACTS 3886378 OPERATING LEASE RIGHT OF USE ASSET 21363878 DUE FROM GAVI AFFILIATES 160986964 RECEIVABLE ON COVAX FACILITY ARRANGEMENTS 220375035 454705417 PROCUREMENT ACCOUNTS PAYABLE 815498262 OPERATING LEASE OBLIGATION 24821321 FOREIGN CURRENCY FORWARD CONTRACTS PAYABLE 135526389 DUE TO GAVI AFFILIATES 9094 REFUNDABLE ADVANCE 300000000 PAYABLE ON COVAX FACILITY ARRANGEMENTS 1851029582 3126884648 X PART X, LINE 2: GAVI IS EXEMPT FROM INCOME TAXES IN EACH OF THE JURISDICTIONS IN WHICH IT HAS OPERATIONS. US GAAP REQUIRES THAT FINANCIAL STATEMENTS REFLECT THE EXPECTED FUTURE TAX CONSEQUENCES OF UNCERTAIN TAX POSITIONS THAT AN ENTITY HAS TAKEN OR EXPECTS TO TAKE ON A TAX RETURN, PRESUMING THE TAX AUTHORITIES' FULL KNOWLEDGE OF THE POSITION AND ALL RELEVANT FACTS. US GAAP ALSO REQUIRES THAT AN ENTITY RECOGNISE THE BENEFIT OF TAX POSITIONS WHEN IT IS MORE LIKELY THAN NOT THAT THE PROVISION WILL BE SUSTAINABLE BASED ON THE MERITS OF THE POSITION. THE GAVI PERFORMED AN EVALUATION OF UNCERTAIN TAX POSITIONS FOR THE YEARS ENDED 31 DECEMBER 2020 AND 2019 AND DETERMINED THAT THERE WERE NO MATTERS THAT WOULD REQUIRE RECOGNITION IN THE FINANCIAL STATEMENTS OR WHICH MAY HAVE ANY EFFECT ON ITS TAX-EXEMPT STATUS. AS OF 31 DECEMBER 2020, THE STATUTES OF LIMITATIONS FOR TAX YEARS 2017 THROUGH 2019 REMAIN OPEN WITH THE UNITED STATES FEDERAL JURISDICTION OR THE VARIOUS STATES AND LOCAL JURISDICTIONS IN WHICH THE GAVI FILES TAX RETURNS. IT IS THE GAVI GROUP'S POLICY TO RECOGNISE INTEREST OR PENALTIES RELATED TO UNCERTAIN TAX POSITIONS, IF ANY, IN INCOME TAX EXPENSE. AS OF 31 DECEMBER 2020 AND 2019, THE GAVI HAD NO ACCRUED INTEREST OR PENALTIES. 1 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION 134378724 SUB-SAHARAN AFRICA 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION 864621258 SOUTH ASIA 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION 418851978 EAST ASIA AND THE PACIFIC 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION 76056850 MIDDLE EAST AND NORTH AFRICA 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION 13925834 RUSSIA AND NEIGHBORING STATES 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION 26260301 CENTRAL AMERICA AND THE CARIBBEAN 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION 5459951 SOUTH AMERICA 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION 1002481 VARIOUS REGIONS 0 0 GRANTS TO RECIPIENTS LOCATED IN VARIOUS REGIONS 367131492 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 INVESTMENTS 3598387140 EUROPE (INCLUDING ICELAND & GREENLAND) 1 267 PROGRAM SERVICES COUNTRY PROGRAMMES MGMT. & OVERSIGHT, POLICY & PERFORMANCE, AND OPERATIONS 53021756 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 FUNDRAISING 18697238 0 0 1 267 1 267 1540557377 4037237626 5577795003 SOUTH ASIA COUNTRY PROGRAMMES 5900996 BOARD APPROVAL/WIRE TRANSFER 14178370 VACCINE SUPPORT FMV SUB-SAHARAN AFRICA COUNTRY PROGRAMMES 1701954 BOARD APPROVAL/WIRE TRANSFER 0 RUSSIA AND NEIGHBORING STATES COUNTRY PROGRAMMES 202411 VACCINE SUPPORT FMV SOUTH ASIA COUNTRY PROGRAMMES 20491981 BOARD APPROVAL/WIRE TRANSFER 44883051 VACCINE SUPPORT & COLD CHAIN EQUIPMENT FMV SUB-SAHARAN AFRICA COUNTRY PROGRAMMES 1369592 BOARD APPROVAL/WIRE TRANSFER 15048963 VACCINE SUPPORT & YELLOW FEVER DIAGNOSTICS FMV SOUTH ASIA COUNTRY PROGRAMMES 79941 VACCINE SUPPORT FMV SOUTH AMERICA COUNTRY PROGRAMMES 954792 VACCINE SUPPORT FMV SUB-SAHARAN AFRICA COUNTRY PROGRAMMES 5671139 BOARD APPROVAL/WIRE TRANSFER 11252578 VACCINE SUPPORT & YELLOW FEVER DIAGNOSTICS FMV SUB-SAHARAN AFRICA COUNTRY PROGRAMMES 3233890 BOARD APPROVAL/WIRE TRANSFER 8317638 VACCINE SUPPORT FMV EAST ASIA AND THE PACIFIC COUNTRY PROGRAMMES 2915381 BOARD APPROVAL/WIRE TRANSFER 5368565 VACCINE SUPPORT FMV SUB-SAHARAN AFRICA COUNTRY PROGRAMMES 4101160 VACCINE SUPPORT & YELLOW FEVER DIAGNOSTICS FMV SUB-SAHARAN AFRICA COUNTRY PROGRAMMES 10630062 BOARD APPROVAL/WIRE TRANSFER 12006342 VACCINE SUPPORT, COLD CHAIN EQUIP., & YELLOW FEVER DIAG. FMV SUB-SAHARAN AFRICA COUNTRY PROGRAMMES 19400285 VACCINE SUPPORT & YELLOW FEVER DIAGNOSTICS FMV SUB-SAHARAN AFRICA COUNTRY PROGRAMMES 734115 BOARD APPROVAL/WIRE TRANSFER 623317 VACCINE SUPPORT FMV SUB-SAHARAN AFRICA COUNTRY PROGRAMMES 2236653 BOARD APPROVAL/WIRE TRANSFER 1273355 VACCINE SUPPORT, COLD CHAIN EQUIP., & YELLOW FEVER DIAG. FMV SUB-SAHARAN AFRICA COUNTRY PROGRAMMES 61747659 BOARD APPROVAL/WIRE TRANSFER 90367731 VACCINE SUPPORT & YELLOW FEVER DIAGNOSTICS FMV SUB-SAHARAN AFRICA COUNTRY PROGRAMMES 8414762 BOARD APPROVAL/WIRE TRANSFER 18936639 VACCINE SUPPORT & YELLOW FEVER DIAGNOSTICS FMV CENTRAL AMERICA AND THE CARIBBEAN COUNTRY PROGRAMMES 173283 VACCINE SUPPORT FMV SUB-SAHARAN AFRICA COUNTRY PROGRAMMES 541842 BOARD APPROVAL/WIRE TRANSFER 252136 VACCINE SUPPORT FMV SUB-SAHARAN AFRICA COUNTRY PROGRAMMES 10232157 BOARD APPROVAL/WIRE TRANSFER 2164546 VACCINE SUPPORT FMV SUB-SAHARAN AFRICA COUNTRY PROGRAMMES 26175742 BOARD APPROVAL/WIRE TRANSFER 56322851 VACCINE SUPPORT & YELLOW FEVER DIAGNOSTICS FMV SUB-SAHARAN AFRICA COUNTRY PROGRAMMES 361735 BOARD APPROVAL/WIRE TRANSFER 1259778 VACCINE SUPPORT & COLD CHAIN EQUIPMENT FMV SUB-SAHARAN AFRICA COUNTRY PROGRAMMES 9113314 VACCINE SUPPORT & YELLOW FEVER DIAGNOSTICS FMV SUB-SAHARAN AFRICA COUNTRY PROGRAMMES 1885764 BOARD APPROVAL/WIRE TRANSFER 3579995 VACCINE SUPPORT & YELLOW FEVER DIAGNOSTICS FMV SUB-SAHARAN AFRICA COUNTRY PROGRAMMES 550349 BOARD APPROVAL/WIRE TRANSFER 1188351 VACCINE SUPPORT & COLD CHAIN EQUIPMENT FMV SOUTH AMERICA COUNTRY PROGRAMMES 47690 VACCINE SUPPORT FMV CENTRAL AMERICA AND THE CARIBBEAN COUNTRY PROGRAMMES 3506482 VACCINE SUPPORT FMV CENTRAL AMERICA AND THE CARIBBEAN COUNTRY PROGRAMMES 769572 VACCINE SUPPORT FMV SOUTH ASIA COUNTRY PROGRAMMES 70071712 VACCINE SUPPORT FMV EAST ASIA AND THE PACIFIC COUNTRY PROGRAMMES 254583 VACCINE SUPPORT FMV SUB-SAHARAN AFRICA COUNTRY PROGRAMMES 5371164 BOARD APPROVAL/WIRE TRANSFER 25570747 VACCINE SUPPORT & YELLOW FEVER DIAGNOSTICS FMV EAST ASIA AND THE PACIFIC COUNTRY PROGRAMMES 15781 VACCINE SUPPORT FMV EAST ASIA AND THE PACIFIC COUNTRY PROGRAMMES 343007 BOARD APPROVAL/WIRE TRANSFER 1359954 VACCINE SUPPORT FMV RUSSIA AND NEIGHBORING STATES COUNTRY PROGRAMMES 1112810 BOARD APPROVAL/WIRE TRANSFER 1941901 VACCINE SUPPORT FMV EAST ASIA AND THE PACIFIC COUNTRY PROGRAMMES 1226022 BOARD APPROVAL/WIRE TRANSFER 2646529 VACCINE SUPPORT & COLD CHAIN EQUIPMENT FMV SUB-SAHARAN AFRICA COUNTRY PROGRAMMES 504070 VACCINE SUPPORT & COLD CHAIN EQUIPMENT FMV SUB-SAHARAN AFRICA COUNTRY PROGRAMMES 1016808 BOARD APPROVAL/WIRE TRANSFER 4002709 VACCINE SUPPORT & YELLOW FEVER DIAGNOSTICS FMV SUB-SAHARAN AFRICA COUNTRY PROGRAMMES 16515468 VACCINE SUPPORT FMV SUB-SAHARAN AFRICA COUNTRY PROGRAMMES 1312806 BOARD APPROVAL/WIRE TRANSFER 16813061 VACCINE SUPPORT FMV SUB-SAHARAN AFRICA COUNTRY PROGRAMMES 9541617 BOARD APPROVAL/WIRE TRANSFER 12202059 VACCINE SUPPORT & YELLOW FEVER DIAGNOSTICS FMV SUB-SAHARAN AFRICA COUNTRY PROGRAMMES 1799668 BOARD APPROVAL/WIRE TRANSFER 3644343 VACCINE SUPPORT FMV RUSSIA AND NEIGHBORING STATES COUNTRY PROGRAMMES 126822 VACCINE SUPPORT FMV EAST ASIA AND THE PACIFIC COUNTRY PROGRAMMES 103449 BOARD APPROVAL/WIRE TRANSFER 1313463 VACCINE SUPPORT FMV SUB-SAHARAN AFRICA COUNTRY PROGRAMMES 6852936 BOARD APPROVAL/WIRE TRANSFER 9090871 VACCINE SUPPORT & COLD CHAIN EQUIPMENT FMV EAST ASIA AND THE PACIFIC COUNTRY PROGRAMMES 24263680 BOARD APPROVAL/WIRE TRANSFER 26857107 VACCINE SUPPORT & COLD CHAIN EQUIPMENT FMV SOUTH ASIA COUNTRY PROGRAMMES 245272 BOARD APPROVAL/WIRE TRANSFER 7877079 VACCINE SUPPORT FMV CENTRAL AMERICA AND THE CARIBBEAN COUNTRY PROGRAMMES 1010614 VACCINE SUPPORT FMV SUB-SAHARAN AFRICA COUNTRY PROGRAMMES 4656850 BOARD APPROVAL/WIRE TRANSFER 13055183 VACCINE SUPPORT & YELLOW FEVER DIAGNOSTICS FMV SUB-SAHARAN AFRICA COUNTRY PROGRAMMES 30639747 BOARD APPROVAL/WIRE TRANSFER 116496328 VACCINE SUPPORT & YELLOW FEVER DIAGNOSTICS FMV SOUTH ASIA COUNTRY PROGRAMMES 26102398 BOARD APPROVAL/WIRE TRANSFER 225363607 VACCINE SUPPORT FMV SUB-SAHARAN AFRICA COUNTRY PROGRAMMES 6392667 BOARD APPROVAL/WIRE TRANSFER 850786 VACCINE SUPPORT FMV SUB-SAHARAN AFRICA COUNTRY PROGRAMMES 2758358 BOARD APPROVAL/WIRE TRANSFER 6110574 VACCINE SUPPORT & COLD CHAIN EQUIPMENT FMV SUB-SAHARAN AFRICA COUNTRY PROGRAMMES 175348 VACCINE SUPPORT FMV SUB-SAHARAN AFRICA COUNTRY PROGRAMMES 5009621 BOARD APPROVAL/WIRE TRANSFER 13737238 VACCINE SUPPORT & YELLOW FEVER DIAGNOSTICS FMV SUB-SAHARAN AFRICA COUNTRY PROGRAMMES 2986528 BOARD APPROVAL/WIRE TRANSFER 2592699 VACCINE SUPPORT FMV SUB-SAHARAN AFRICA COUNTRY PROGRAMMES 89830 VACCINE SUPPORT FMV SUB-SAHARAN AFRICA COUNTRY PROGRAMMES 5900 BOARD APPROVAL/WIRE TRANSFER 1481662 VACCINE SUPPORT FMV EAST ASIA AND THE PACIFIC COUNTRY PROGRAMMES 307157 VACCINE SUPPORT FMV SUB-SAHARAN AFRICA COUNTRY PROGRAMMES 720000 BOARD APPROVAL/WIRE TRANSFER 1358095 VACCINE SUPPORT & YELLOW FEVER DIAGNOSTICS FMV SUB-SAHARAN AFRICA COUNTRY PROGRAMMES 19911800 VACCINE SUPPORT & YELLOW FEVER DIAGNOSTICS FMV MIDDLE EAST AND NORTH AFRICA COUNTRY PROGRAMMES 1441830 VACCINE SUPPORT FMV RUSSIA AND NEIGHBORING STATES COUNTRY PROGRAMMES 6043986 BOARD APPROVAL/WIRE TRANSFER 5711455 VACCINE SUPPORT FMV SUB-SAHARAN AFRICA COUNTRY PROGRAMMES 3264617 BOARD APPROVAL/WIRE TRANSFER 30594949 VACCINE SUPPORT FMV EAST ASIA AND THE PACIFIC COUNTRY PROGRAMMES 47667 VACCINE SUPPORT FMV SUB-SAHARAN AFRICA COUNTRY PROGRAMMES 134999 BOARD APPROVAL/WIRE TRANSFER 2275943 VACCINE SUPPORT & YELLOW FEVER DIAGNOSTICS FMV SUB-SAHARAN AFRICA COUNTRY PROGRAMMES 10740137 BOARD APPROVAL/WIRE TRANSFER 29156199 VACCINE SUPPORT & YELLOW FEVER DIAGNOSTICS FMV RUSSIA AND NEIGHBORING STATES COUNTRY PROGRAMMES 4957236 BOARD APPROVAL/WIRE TRANSFER 6163680 VACCINE SUPPORT FMV EAST ASIA AND THE PACIFIC COUNTRY PROGRAMMES 250000 BOARD APPROVAL/WIRE TRANSFER 4640713 VACCINE SUPPORT & COLD CHAIN EQUIPMENT FMV MIDDLE EAST AND NORTH AFRICA COUNTRY PROGRAMMES 12484003 VACCINE SUPPORT & COLD CHAIN EQUIPMENT FMV SUB-SAHARAN AFRICA COUNTRY PROGRAMMES 5287876 BOARD APPROVAL/WIRE TRANSFER 17156877 VACCINE SUPPORT & COLD CHAIN EQUIPMENT FMV SUB-SAHARAN AFRICA COUNTRY PROGRAMMES 12740134 BOARD APPROVAL/WIRE TRANSFER 13759712 VACCINE SUPPORT & COLD CHAIN EQUIPMENT FMV VARIOUS REGIONS INVESTMENT CASES, VACCINE RELATED PROGRAMME 0 115396166 VACCINE FMV VARIOUS REGIONS FOC, VACCINE RELATED PROGRAMME 0 51650795 VACCINE SUPPORT FMV VARIOUS REGIONS VACCINE RESEARCH AND DEVELOPMENT ACTIVITIES 200084532 BOARD APPROVAL/WIRE TRANSFER 0 EAST ASIA AND THE PACIFIC WORK PLAN 3393259 BOARD APPROVAL/WIRE TRANSFER 0 EUROPE (INCLUDING ICELAND & GREENLAND) WORK PLAN 318925 BOARD APPROVAL/WIRE TRANSFER 0 SUB-SAHARAN AFRICA WORK PLAN 144214 BOARD APPROVAL/WIRE TRANSFER 0 SUB-SAHARAN AFRICA WORK PLAN 33981 BOARD APPROVAL/WIRE TRANSFER 0 EUROPE (INCLUDING ICELAND & GREENLAND) WORK PLAN 590311 BOARD APPROVAL/WIRE TRANSFER 0 SUB-SAHARAN AFRICA WORK PLAN 896949 BOARD APPROVAL/WIRE TRANSFER 0 SUB-SAHARAN AFRICA WORK PLAN 26795 BOARD APPROVAL/WIRE TRANSFER 0 EUROPE (INCLUDING ICELAND & GREENLAND) WORK PLAN 1000 BOARD APPROVAL/WIRE TRANSFER 0 EUROPE (INCLUDING ICELAND & GREENLAND) WORK PLAN 253922 BOARD APPROVAL/WIRE TRANSFER 0 SUB-SAHARAN AFRICA WORK PLAN 33211 BOARD APPROVAL/WIRE TRANSFER 0 EUROPE (INCLUDING ICELAND & GREENLAND) WORK PLAN 68000 BOARD APPROVAL/WIRE TRANSFER 0 SUB-SAHARAN AFRICA WORK PLAN 177543 BOARD APPROVAL/WIRE TRANSFER 0 SUB-SAHARAN AFRICA WORK PLAN 334274 BOARD APPROVAL/WIRE TRANSFER 0 SOUTH ASIA WORK PLAN 77436 BOARD APPROVAL/WIRE TRANSFER 0 EUROPE (INCLUDING ICELAND & GREENLAND) WORK PLAN 1944567 BOARD APPROVAL/WIRE TRANSFER 0 SUB-SAHARAN AFRICA WORK PLAN 2166 BOARD APPROVAL/WIRE TRANSFER 0 EUROPE (INCLUDING ICELAND & GREENLAND) WORK PLAN 139240 BOARD APPROVAL/WIRE TRANSFER 0 EUROPE (INCLUDING ICELAND & GREENLAND) WORK PLAN 20399 BOARD APPROVAL/WIRE TRANSFER 0 SUB-SAHARAN AFRICA WORK PLAN 112248 BOARD APPROVAL/WIRE TRANSFER 0 EAST ASIA AND THE PACIFIC WORK PLAN 137966 BOARD APPROVAL/WIRE TRANSFER 0 EUROPE (INCLUDING ICELAND & GREENLAND) WORK PLAN 297467 BOARD APPROVAL/WIRE TRANSFER 0 SUB-SAHARAN AFRICA WORK PLAN 176344 BOARD APPROVAL/WIRE TRANSFER 0 SUB-SAHARAN AFRICA WORK PLAN 711048 BOARD APPROVAL/WIRE TRANSFER 0 EUROPE (INCLUDING ICELAND & GREENLAND) WORK PLAN 848658 BOARD APPROVAL/WIRE TRANSFER 0 SOUTH ASIA WORK PLAN 2426307 BOARD APPROVAL/WIRE TRANSFER 0 SUB-SAHARAN AFRICA WORK PLAN 60544 BOARD APPROVAL/WIRE TRANSFER 0 SUB-SAHARAN AFRICA WORK PLAN 225105 BOARD APPROVAL/WIRE TRANSFER 0 EUROPE (INCLUDING ICELAND & GREENLAND) WORK PLAN 1300000 BOARD APPROVAL/WIRE TRANSFER 0 SUB-SAHARAN AFRICA WORK PLAN 391488 BOARD APPROVAL/WIRE TRANSFER 0 SUB-SAHARAN AFRICA WORK PLAN 44080 BOARD APPROVAL/WIRE TRANSFER 0 EUROPE (INCLUDING ICELAND & GREENLAND) WORK PLAN 339328 BOARD APPROVAL/WIRE TRANSFER 0 EUROPE (INCLUDING ICELAND & GREENLAND) WORK PLAN 32042 BOARD APPROVAL/WIRE TRANSFER 0 EUROPE (INCLUDING ICELAND & GREENLAND) WORK PLAN 119937 BOARD APPROVAL/WIRE TRANSFER 0 EUROPE (INCLUDING ICELAND & GREENLAND) WORK PLAN 145409 BOARD APPROVAL/WIRE TRANSFER 0 EUROPE (INCLUDING ICELAND & GREENLAND) WORK PLAN 17500 BOARD APPROVAL/WIRE TRANSFER 0 SUB-SAHARAN AFRICA WORK PLAN 141208 BOARD APPROVAL/WIRE TRANSFER 0 SOUTH ASIA WORK PLAN 476460 BOARD APPROVAL/WIRE TRANSFER 0 EUROPE (INCLUDING ICELAND & GREENLAND) WORK PLAN 1211885 BOARD APPROVAL/WIRE TRANSFER 0 EUROPE (INCLUDING ICELAND & GREENLAND) WORK PLAN 115959 BOARD APPROVAL/WIRE TRANSFER 0 EUROPE (INCLUDING ICELAND & GREENLAND) WORK PLAN 38821 BOARD APPROVAL/WIRE TRANSFER 0 SUB-SAHARAN AFRICA WORK PLAN 254718 BOARD APPROVAL/WIRE TRANSFER 0 EUROPE (INCLUDING ICELAND & GREENLAND) WORK PLAN 166164 BOARD APPROVAL/WIRE TRANSFER 0 EUROPE (INCLUDING ICELAND & GREENLAND) WORK PLAN 251065 BOARD APPROVAL/WIRE TRANSFER 0 SUB-SAHARAN AFRICA WORK PLAN 56001 BOARD APPROVAL/WIRE TRANSFER 0 EAST ASIA AND THE PACIFIC WORK PLAN 559444 BOARD APPROVAL/WIRE TRANSFER 0 EUROPE (INCLUDING ICELAND & GREENLAND) WORK PLAN 46440 BOARD APPROVAL/WIRE TRANSFER 0 SUB-SAHARAN AFRICA WORK PLAN 195484 BOARD APPROVAL/WIRE TRANSFER 0 SUB-SAHARAN AFRICA WORK PLAN 143831 BOARD APPROVAL/WIRE TRANSFER 0 SUB-SAHARAN AFRICA WORK PLAN 119835 BOARD APPROVAL/WIRE TRANSFER 0 SUB-SAHARAN AFRICA WORK PLAN 1000 BOARD APPROVAL/WIRE TRANSFER 0 EUROPE (INCLUDING ICELAND & GREENLAND) WORK PLAN 229767 BOARD APPROVAL/WIRE TRANSFER 0 EUROPE (INCLUDING ICELAND & GREENLAND) WORK PLAN 430000 BOARD APPROVAL/WIRE TRANSFER 0 SUB-SAHARAN AFRICA WORK PLAN 448166 BOARD APPROVAL/WIRE TRANSFER 0 SUB-SAHARAN AFRICA WORK PLAN 251161 BOARD APPROVAL/WIRE TRANSFER 0 EUROPE (INCLUDING ICELAND & GREENLAND) WORK PLAN 1518192 BOARD APPROVAL/WIRE TRANSFER 0 EUROPE (INCLUDING ICELAND & GREENLAND) WORK PLAN 186085 BOARD APPROVAL/WIRE TRANSFER 0 SUB-SAHARAN AFRICA WORK PLAN 302316 BOARD APPROVAL/WIRE TRANSFER 0 SOUTH ASIA WORK PLAN 504990 BOARD APPROVAL/WIRE TRANSFER 0 EAST ASIA AND THE PACIFIC WORK PLAN 53122 BOARD APPROVAL/WIRE TRANSFER 0 SOUTH ASIA WORK PLAN 172378 BOARD APPROVAL/WIRE TRANSFER 0 EUROPE (INCLUDING ICELAND & GREENLAND) WORK PLAN 2365959 BOARD APPROVAL/WIRE TRANSFER 0 EUROPE (INCLUDING ICELAND & GREENLAND) WORK PLAN 26540000 BOARD APPROVAL/WIRE TRANSFER 0 EUROPE (INCLUDING ICELAND & GREENLAND) WORK PLAN 2255825 BOARD APPROVAL/WIRE TRANSFER 0 EUROPE (INCLUDING ICELAND & GREENLAND) WORK PLAN 705274 BOARD APPROVAL/WIRE TRANSFER 0 SUB-SAHARAN AFRICA WORK PLAN 262172 BOARD APPROVAL/WIRE TRANSFER 0 EUROPE (INCLUDING ICELAND & GREENLAND) WORK PLAN 91770880 BOARD APPROVAL/WIRE TRANSFER 0 EUROPE (INCLUDING ICELAND & GREENLAND) WORK PLAN 109702 BOARD APPROVAL/WIRE TRANSFER 0 24 117 1 0 0 0 0 1 PART I, LINE 2: GAVI MONITORS THE USE OF GRANT SUPPORT AND PROTECTS AGAINST CORRUPTION AND FRAUD THROUGH COLLABORATION WITH PARTNERS, THROUGH THE MAINTENANCE AND IMPLEMENTATION OF ROBUST POLICIES AND PROCEDURES, GRANT TERMS AND CONDITIONS, AND AN AUDIT AND INVESTIGATIONS FUNCTION. POLICIES AND PROCEDURES: ALL APPLICATIONS FOR NEW SUPPORT, AND REQUESTS FOR CONTINUED SUPPORT, REQUIRE AN ENDORSEMENT AND SIGNATURES FROM A NATIONAL COORDINATION BODY WHICH IN THE CASE OF NEW VACCINES SUPPORT, IS THE INTER-AGENCY COORDINATION COMMITTEE (ICC). THE ICC INCLUDES ON ITS MEMBERSHIP, IN ADDITION TO HIGH LEVEL REPRESENTATION OF THE GOVERNMENT OF GAVI COUNTRIES, GAVI PARTNERS SUCH AS THE WORLD HEALTH ORGANIZATION, UNICEF, NONGOVERNMENTAL ORGANIZATIONS AND DONOR GOVERNMENTS. IN THE CASE OF CASH SUPPORT FOR HEALTH SYSTEM STRENGTHENING, ENDORSEMENT IS REQUIRED FROM THE HEALTH SECTOR COORDINATION COMMITTEE (HSCC) OR OTHER SIMILAR INTER-AGENCY COMMITTEE WHICH ALSO INCLUDES THE GOVERNMENT, BILATERAL, MULTILATERAL AGENCIES AND CIVIL SOCIETY REPRESENTATIVES. IN ADDITION, THE APPLICATIONS SUBMITTED MUST INCLUDE THE SIGNATURES OF THE MINISTER OF HEALTH AND THE MINISTER OF FINANCE. THE GAVI NEW APPLICATIONS GUIDELINES PROVIDE DETAILS ON GAVI SUPPORT, INCLUDING GENERAL PRINCIPLES AND THE PROCESS FOR APPLYING AND MONITORING ACTIVITIES. A PARTNERSHIP FRAMEWORK AGREEMENT IS ENTERED INTO BETWEEN GAVI AND COUNTRIES THAT SETS OUT THE TERMS AND CONDITIONS GOVERNING GAVI SUPPORT. THE MAIN TOOLS/APPROACHES USED BY GAVI TO MONITOR THE USE OF GAVI SUPPORT ARE THE FOLLOWING: (1) IN-COUNTRY COORDINATING AND SUPERVISORY COMMITTEES (ICC AND HSCC); (2) ROUTINE MONITORING MISSIONS IN-COUNTRY, LED BY SENIOR COUNTRY MANAGERS, WORKING WITH PARTNERS AND IN-COUNTRY COUNTERPARTS AS WELL AS FORMAL ANNUAL JOINT APPRAISALS THAT REVIEW PERFORMANCE OF ALL GRANTS; (3) FOR CASH GRANTS - ONGOING INTERNAL AND PERIODIC EXTERNAL AUDITS ON TOP OF ROUTINE FINANCIAL REPORTING REQUIREMENTS; (4) THE PROGRAMME CAPACITY ASSESSMENTS THAT INDEPENDENTLY ASSESS FINANCIAL MANAGEMENT ARRANGEMENTS AND PROGRAMMATIC/MANAGEMENT CAPACITIES IN-COUNTRY AS WELL AS INVESTIGATIONS IN CASES OF SUSPECTED OR ACTUAL MISUSE OF FUNDS; AND (5) ROUTINE QUANTITATIVE AND QUALITATIVE REPORTING THROUGH GRANT PERFORMANCE FRAMEWORKS, REQUIRED REPORTS/EVALUATIONS/SURVEYS/ASSESSMENTS SUBMITTED TO GAVI BY RECIPIENT GOVERNMENTS AND ASSESSED BY THE HIGH-LEVEL REVIEW PANEL/SENIOR MANAGEMENT. COLLABORATION WITH PARTNERS: GAVI MAINTAINS FORMAL AND INFORMAL CONTACT WITH THE PARTNERS (THE BILL & MELINDA GATES FOUNDATION, UNICEF, WHO, THE WORLD BANK GROUP, CIVIL SOCIETY ORGANIZATIONS, IMPLEMENTING COUNTRY GOVERNMENTS, IMPLEMENTING COUNTRY PHARMACEUTICAL INDUSTRY, INDUSTRIALISED COUNTRY GOVERNMENTS, INDUSTRIALISED COUNTRY PHARMACEUTICAL INDUSTRY, RESEARCH AND TECHNICAL HEALTH INSTITUTES) AT VARIOUS LEVELS TO HELP ENSURE THAT RELEVANT INFORMATION ABOUT SUSPECTED AND ACTUAL CASES OF CORRUPTION AND MISUSE OF FUNDS IS SHARED ON A TIMELY BASIS. GAVI ENGAGES UNICEF, A KEY PARTNER IN GAVI, THE VACCINE ALLIANCE, FOR THE PURCHASE AND DELIVERY OF VACCINES. UNICEF MANAGES VACCINE LOGISTICS AND DELIVERY IN ACCORDANCE WITH ITS INTERNAL CONTROLS AND INTERNAL AND EXTERNAL AUDITS AS MANDATED BY ITS MEMBER STATES. GAVI AND UNICEF HAVE ENTERED INTO VARIOUS AGREEMENTS WHICH PROVIDE FOR CONFIRMATIONS, ASSURANCES AND INFORMATION REGARDING UNICEF ACTIVITIES CARRIED OUT ON BEHALF OF THE ALLIANCE. AUDIT AND INVESTIGATIONS: THE PRIMARY RESPONSIBILITY OF THE AUDIT AND INVESTIGATIONS FUNCTION IS TO EVALUATE AND THUS HELP STRENGTHEN RISK MANAGEMENT, CONTROL AND GOVERNANCE PROCESSES WITHIN THE SECRETARIAT, A RESPONSIBILITY WHICH EXTENDS TO THE PROGRAMS AND ACTIVITIES OF IMPLEMENTING COUNTRIES AND PARTNERS. THE MANAGING DIRECTOR OF AUDIT AND INVESTIGATION REPORTS TO GAVI'S BOARD OF DIRECTORS, WHICH IS ACHIEVED THROUGH ROUTINE REPORTING TO THE AUDIT AND FINANCE COMMITTEE, AND THE CHIEF EXECUTIVE OFFICER. THE BOARD OF DIRECTORS SOLELY HAS THE AUTHORITY TO APPOINT AND TERMINATE THE MANAGING DIRECTOR OF AUDIT AND INVESTIGATIONS UPON THE RECOMMENDATION OF THE AUDIT AND FINANCE COMMITTEE. THE TRANSPARENCY AND ACCOUNTABILITY POLICY (TAP): THROUGH TAP, GAVI IS ABLE TO ENSURE THAT ALL GAVI SUPPORT AT COUNTRY LEVEL IS MANAGED IN A TRANSPARENT AND ACCOUNTABLE MANNER THROUGH SYSTEMS THAT INCLUDE APPROPRIATE OVERSIGHT MECHANISMS, AND THAT THE SUPPORT IS USED ACCORDING TO THE PROGRAMME OBJECTIVES AS OUTLINED IN INDIVIDUAL COUNTRY AGREEMENTS. THE POLICY GOVERNS THE TRANSPARENCY AND ACCOUNTABILITY ASPECTS OF GAVI SUPPORT PROVIDED IN THE FORM OF CASH, VACCINES AND VACCINE DEVICES AT COUNTRY LEVEL. THE PRINCIPLES GOVERNING TAP INCLUDE: RESPECT AID EFFECTIVENESS PRINCIPLES; FOCUS ON PREVENTION; RELATE MONITORING TO RISK; PROMOTE FLEXIBILITY AND COUNTRY OWNERSHIP; PROMOTE MUTUAL ACCOUNTABILITY; AND STRENGTHEN COUNTRY SYSTEMS. TAP AIMS TO RETAIN FLEXIBLE AND NON-PERSPECTIVE APPROACH TO ALLOW FOR DIFFERENCES IN COUNTRY CONTEXT AND ENHANCES CONTINUED EFFORTS BY GAVI TO SUPPORT SUSTAINABLE DEVELOPMENT OF COUNTRY CAPACITY. PART I, LINE 3: THE ALLIANCE REPORTED THE EXPENDITURES BASED ON THE ACCOUNTING METHOD USED IN ITS AUDITED FINANCIAL STATEMENTS WHICH IS ON AN ACCRUAL BASIS. PART III ACCOUNTING METHOD: PART I, LINE 3, COLUMN (D) RECIPIENTS REFER TO COUNTRIES OR PARTNERS LOCATED IN THE REGION. PART II, LINE 1 THE ALLIANCE REPORTED THE EXPENDITURES BASED ON THE ACCOUNTING METHOD USED IN ITS AUDITED FINANCIAL STATEMENTS WHICH IS ON AN ACCRUAL BASIS. 1 ALBERT B SABIN VACCINE INSTITUTE 2000 PENSYLVANIA AVE NW SUITE 7100 WASHINGTON DC DC 20006 061389829 501(C)(3) 123557 PARTNER SUPPORT BIOSTAT GLOBAL CONSULTING LLC 330 BLANDFORD DR KILBOURNE VILLAGE WORTHINGTON OH 43085 471274029 60415 PARTNER SUPPORT BROWN CONSULTING GROUP INTERNATIONAL LLC 19701 BETHEL CHURCH ROAD STE 103 168 CORNELIUS NC 28031 118117 PARTNER SUPPORT CARDNO EMERGING MARKETS USA LTD COLONIAL PLACE III 2107 WILSON BOULEVARD SUITE 800 ARLINGTON VA 22201 278555 PARTNER SUPPORT CATHOLIC RELIEF SERVICES 228 WEST LEXINGTON STREET BALTIMORE MD 21201 135563422 501(C)(3) 40094 PARTNER SUPPORT CENTERS FOR DISEASE CONTROL AND PREVENTION 1600 CLIFTON ROAD ATLANTA GA 30303 CDC 2586854 PARTNER SUPPORT CDC FOUNDATION 600 PEACHTREE ST NE SUITE 1000 ATLANTA GA 30303 582106707 501(C)(3) 5350451 PARTNER SUPPORT CLINTON HEALTH ACCESS INITIATIVE 383 DORCHESTER AVENUE SUITE 400 BOSTON MA 02127 271414646 501(C)(3) 3439868 PARTNER SUPPORT FRAYM INC 3101 WILSON BLVD SUITE 300 ARLINGTON VA 22201 813857001 67500 PARTNER SUPPORT GLOBAL DEVELOPMENT SUPPORT 1300 L STREET NW SUITE 920 WASHINGTON DC DC 20005 82718 PARTNER SUPPORT HARVARD - PRESIDENT AND FELLOWS OF HARVARD COLLEGE 1033 MASSACHUSSETS AVENUE CAMBRIDGE MA 02138 042103580 501(C)(3) 9728 PARTNER SUPPORT JHPIEGO 1615 THAMES STREET BALTIMORE MD 21231 237424444 501(C)(3) 1200330 PARTNER SUPPORT JOHNS HOPKINS UNIVERSITY 1101 E33RD STREET SUITE D200 BALTIMORE MD 21218 520595110 501(C)(3) 534104 PARTNER SUPPORT JSI RESEARCH & TRAINING INSTITUTE INC 2733 CRYSTAL DRIVE 4TH FLOOR ARLINGTON VA 22202 042679824 501(C)(3) 4564165 PARTNER SUPPORT KATI COLLECTIVE INC 13346 108TH AVENUE SW VASHON WA 98070 57937 PARTNER SUPPORT LIVING GOODS 220 HALLECK ST SUITE 2008 SAN FRANCISCO CA 94129 205010527 501(C)(3) 8063 PARTNER SUPPORT MASTERCARD INTERNATIONAL INC 200 PURCHASE STREET NEW YORK NY 10577 952536378 1048071 PARTNER SUPPORT NEXLEAF ANALYTICS 1964 WESTWOOD BLVD LOS ANGELES CA 90025 900514027 501(C)(3) 1278797 PARTNER SUPPORT PAN AMERICAN SANITARY BUREAU 525 TWENTY-THIRD STEET NW WASHINGTON DC 20037 PASB 870980 PARTNER SUPPORT PATH 2201 WESTLAKE AVENUE SEATTLE WA 98109 911157127 501(C)(3) 2686834 PARTNER SUPPORT PREMISE DATA CORPORATION 185 BERRY STREET SUITE 6850 SAN FRANCISCO CA 94107 455294131 73500 PARTNER SUPPORT RESULTS FOR DEVELOPMENT INSTITUTE 1111 19TH STREET NW SUITE 700 WASHINGTON DC 20036 208530747 501(C)(3) 876833 PARTNER SUPPORT TASK FORCE FOR GLOBAL HEALTH INC 330 WEST PONCE DE LEON AVENUE DECATUR GA 30030 581698648 501(C)(3) 639452 PARTNER SUPPORT THE ASPEN INSTITUTE 2300 N STREET NW SUITE 700 WASHINGTON DC 20037 840399006 501(C)(3) 193929 PARTNER SUPPORT THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 615 WEST 131ST STREET NEW YORK NY 10027 1869183 PARTNER SUPPORT THE WORLD BANK (IBRD) 1818 H STREET WASHINGTON DC 20433 THE WORLD BANK 7361004 PARTNER SUPPORT UNICEF 333 EAST 38TH STREET NEW YORK NY 10116 131760110 501(C)(3) 66234203 PROCUREMENT FEE & PARTNER SUPPORT VILLAGE REACH 2900 EASTLAKE AVE E SUITE 230 SEATTLE WA 98102 912083484 501(C)(3) 1573680 PARTNER SUPPORT YALE UNIVERSITY PO BOX 1873 NEW HAVEN CT 06508 060646973 501(C)(3) 1084035 PARTNER SUPPORT ZENYSIS TECHNOLOGIES INC 2325 3RD ST NUMBER 213 SAN FRANCISCO CA 94107 886850 PARTNER SUPPORT ZIPLINE INTERNATIONAL INC 495 PINE AVENUE HALF MOON BAY CA 94019 453197601 850000 PARTNER SUPPORT EMORY UNIVERSITY 201 DOWNMAN DR ATLANTA GA 30322 580566256 501(C)(3) 358598 PARTNER SUPPORT JOHN SNOW INC 44 FARNSWORTH STREET BOSTON MA 02210 042578580 15538 PARTNER SUPPORT 19 14 PART I, LINE 2: GAVI MONITORS THE USE OF GRANT FUNDS INSIDE THE US THROUGH THE FOLLOWING WAYS: (I) THROUGH ANNUAL TECHNICAL PROGRESS REPORTS AND CERTIFIED FINANCIAL REPORTS FROM GRANTEES THAT SUPPORT THE ACHIEVEMENT OF MILESTONES STIPULATED IN THE GRANT AGREEMENTS. REPORTS ARE RECEIVED AND REVIEWED BY THE GAVI POLICY AND PERFORMANCE TEAM; AND (II) THROUGH GRANT EVALUATIONS PERFORMED BY INDEPENDENT CONSULTANTS DURING THE CONTRACT PERIOD. X X 1 1 X X X 0 0 0 0 0 0 0 0 0 DR SETH BERKLEY CHIEF EXECUTIVE OFFICER 416357 0 16490 0 217013 0 93826 0 20846 0 764532 0 0 0 ANURADHA GUPTA DEPUTY CHIEF EXECUTIVE OFFICER 334117 0 16706 0 0 0 75294 0 10558 0 436675 0 0 0 SIMON LAMB MNG DIR, AUDIT & INVESTIGATIONS 276391 0 5528 0 0 0 62286 0 10558 0 354763 0 0 0 ELIZABETH DAVIES HEAD HUMAN RESOURCES 165993 0 0 0 145799 0 34109 0 5279 0 351180 0 0 0 ALEX DE FAUQUE DE JONQUIERES DIR. HEALTH SYS. & IMMUNE. STRENGTH. 226260 0 0 0 51846 0 49524 0 14337 0 341967 0 0 0 PASCAL BAROLLIER MANAGING DIR, PUBLIC ENGAGEMENT 259656 0 0 0 0 0 58187 0 23335 0 341178 0 0 0 EDMUND GROVE DIRECTOR PROGRAMME AUDIT 220072 0 0 0 51846 0 47907 0 14337 0 334162 0 0 0 ANDREW MENDS DIRECTOR OPERATIONS 218868 0 0 0 51846 0 47579 0 14337 0 332630 0 0 0 MARIE-ANGE SARAKA-YAO MANAGING DIR, RES MOBL./PARTNERSHIPS 265703 0 0 0 0 0 59792 0 5279 0 330774 0 0 0 THABANI MAPHOSA MANAGING DIR, COUNTRY PROGRAM 216814 0 0 0 51846 0 47133 0 14337 0 330130 0 0 0 AURELIA NGUYEN OFFICE OF THE COVAX FACILITY 262206 0 0 0 0 0 58840 0 9058 0 330104 0 0 0 ASSIETOU DIOUF MNG DIR, FIN & OPS. 225405 0 0 0 0 0 49336 0 21115 0 295856 0 0 0 PHILIP ARMSTRONG DIRECTOR, GOVERNANCE- UNTIL 07/2020 165715 0 0 0 18413 0 36148 0 7918 0 228194 0 0 0 BRENDA KILLEN DIRECTOR, GOVERNANCE - AS OF 07/2020 115995 0 0 0 51846 0 24795 0 8363 0 200999 0 0 0 PART I, LINE 1A UNDER AN AGREEMENT WITH THE SWISS GOVERNMENT, NON-SWISS EMPLOYEES OF THE GAVI ALLIANCE WORKING IN GENEVA, SWITZERLAND ARE EXEMPT FROM SWISS FEDERAL, CANTONAL AND COMMUNAL TAXES ON SALARIES AND ALLOWANCES PAID TO THEM BY THE GAVI ALLIANCE. AS THE GAVI ALLIANCE IN GENEVA OPERATES AN INTERNAL TAX SCHEME, EMPLOYEES OF SWISS NATIONALITY ARE ALSO EXEMPT FROM SWISS FEDERAL, CANTONAL AND COMMUNAL TAXES ON SALARIES AND ALLOWANCES PAID TO THEM BY THE GAVI ALLIANCE. TO ENSURE EQUITY AMONGST GAVI EMPLOYEES, CERTAIN ELIGIBLE EMPLOYEES WHO HAVE A FOREIGN TAX LIABILITY ON THEIR GAVI SALARY AND ALLOWANCES (E.G. US NATIONALS AND EMPLOYEES LIVING IN FRANCE) MAY RECEIVE ASSISTANCE FROM GAVI IN MEETING THEIR TAX OBLIGATIONS IN ACCORDANCE WITH GAVI'S FOREIGN TAX POLICY. IN ADDITION, FOR THE YEAR ENDED DECEMBER 31, 2020, THE CHIEF EXECUTIVE OFFICER RECEIVED A HOUSING ALLOWANCE WHICH WAS TREATED AS TAXABLE COMPENSATION. SCHEDULE J, PART II, COLUMN (B)(III): OTHER REPORTABLE COMPENSATION - THIS INCLUDES ALLOWANCES DUE TO EMPLOYEES UNDER GAVI'S HR POLICY, INCLUDING ALLOWANCES FOR RELOCATION, EDUCATION GRANT AND REIMBURSEMENT OF NON-SWISS TAXES ON GAVI INCOME. SCHEDULE J, PART II: GAVI REPORTED COMPENSATION ALL VALUES IN SWISS FRANCS (CHF) A B C D E F G BONUS OTHER REPORTED COMP RETIRE NONTAX BASE AND TAX EDU MENT ABLE COMP INC REIMB GRANT BENEFITS PLAN HEALTH INS DR. SETH BERKLEY 2019 384,832 0 155,929 48,400 18,000 86,723 14,112 2020 388,682 15,394 136,189 48,400 18,000 87,590 19,460 BRENDA KILLEN 2020 108,285 0 0 48,400 0 23,147 7,807 ASSIETOU DIOUF 2019 156,572 0 0 0 17,397 34,200 10,752 2020 210,423 0 0 0 0 46,057 19,712 PHILIP ARMSTRONG 2019 186,135 0 0 0 0 40,464 6,571 2020 154,700 0 17,189 0 0 33,475 7,392 ANURADHA GUPTA 2019 311,909 3,110 0 0 0 70,289 7,168 2020 311,909 15,595 0 0 0 70,289 9,856 THABANI MAPHOSA 2020 202,403 0 0 48,400 0 44,000 13,384 PASCAL BAROLLIER 2019 240,334 0 0 0 0 53,781 16,255 2020 242,397 0 0 0 0 54,319 21,784 MARIE-ANGE SARAKA-YAO 2019 245,930 0 0 0 0 55,265 3,584 2020 248,042 0 0 0 0 55,818 4,928 AURELIA NGUYEN 2019 234,760 0 0 0 0 52,314 6,132 2020 244,778 0 0 0 0 54,929 8,456 SIMON LAMB 2019 258,020 903 0 0 0 58,145 12,176 2020 258,020 5,160 0 0 0 58,146 9,856 ELIZABETH DAVIES 2020 154,960 0 0 136,108* 0 31,842 4,928 ALEX DE FAUQUE DE JONQUIERES 2019 207,789 0 0 48,400 0 45,325 9,716 2020 211,221 0 0 48,400 0 46,232 13,384 EDMUND GROVE 2019 203,684 0 0 48,400 0 44,279 9,716 2020 205,444 0 0 48,400 0 44,723 13,384 ANDREW MENDS 2020 204,320 0 0 48,400 0 44,417 13,384 * THIS AMOUNT REPRESENTS THE EDUCATION GRANT FOR TWO YEARS WHICH WAS EXCEPTIONALLY PAID IN ONE CALENDAR YEAR. THE CHF-USD EXCHANGE RATE IS 1.00698 IN 2019 AND 1.07120 IN 2020. THE FULL TEXT OF THE ABBREVIATED HEADINGS IN THE TABLE ABOVE ARE AS FOLLOWS: A - BASE COMPENSATION B - BONUS AND INCENTIVE "OTHER REPORTED COMPENSATION" INCLUDES THE FOLLOWING: C - US TAX REIMBURSEMENT D - EDUCATION GRANT E - OTHER BENEFITS F - RETIREMENT PLAN G - NON-TAXABLE HEALTH INSURANCE SCHEDULE J, PART III: ALL OF GAVI ALLIANCE'S HIGHEST COMPENSATED EMPLOYEES ARE BASED IN GENEVA, SWITZERLAND. THESE EMPLOYEES' SALARIES REFLECTED THE COST OF LIVING IN GENEVA AND INCLUDE BENEFITS SUCH AS EDUCATION GRANT. THE BENEFITS PROVIDED TO EMPLOYEES ARE COMPARABLE TO THOSE PROVIDED BY OTHER INTERNATIONAL NOT-FOR-PROFIT ORGANISATIONS. FORM 990, PART III, LINE 2 IN APRIL 2020, THE WORLD HEALTH ORGANIZATION ("WHO") HOSTED THE LAUNCH OF THE ACCESS TO COVID-19 TOOLS ("ACT") ACCELERATOR, A NEW GLOBAL COLLABORATION TO ACCELERATE DEVELOPMENT, PRODUCTION, AND EQUITABLE ACCESS TO COVID-19 DIAGNOSTICS, THERAPEUTICS AND VACCINES. WITHIN THE ACCELERATOR, GAVI ALLIANCE ("GAVI"), THE COALITION FOR EPIDEMIC PREPAREDNESS INNOVATIONS ("CEPI") AND WHO TOGETHER WITH MULTINATIONAL AND DEVELOPING COUNTRY VACCINE MANUFACTURERS ARE WORKING ON THE COVID-19 VACCINE PILLAR AND LAUNCHED THE COVAX FACILITY (THE "FACILITY") AS A GLOBAL RISK-SHARING MECHANISM FOR POOLED PROCUREMENT AND EQUITABLE DISTRIBUTION OF EVENTUAL COVID-19 VACCINES. GAVI ESTABLISHED THE OFFICE OF THE COVAX FACILITY TO EXECUTE ITS RESPONSIBILITIES AS THE LEGAL ENTITY TO ADMINISTER THE FACILITY. GAVI IS COORDINATING THE DEVELOPMENT AND IMPLEMENTATION OF THE FACILITY. THE FACILITY WILL MAKE INVESTMENTS ACROSS A BROAD PORTFOLIO OF PROMISING VACCINE CANDIDATES (INCLUDING THOSE BEING SUPPORTED BY CEPI) TO MAKE SURE AT-RISK INVESTMENT IN MANUFACTURING HAPPENS TO SUPPORT THE DEVELOPMENT OF VACCINES WHICH ARE SAFE AND EFFECTIVE AS QUICKLY AS POSSIBLE. THIS MEANS THE FACILITY, BY POOLING PURCHASING POWER FROM ALL COUNTRIES THAT PARTICIPATE, WILL HAVE RAPID ACCESS TO DOSES OF SAFE AND EFFECTIVE VACCINES AS SOON AS THEY RECEIVE REGULATORY APPROVAL. GUIDED BY AN ALLOCATION FRAMEWORK BEING DEVELOPED BY WHO, THE FACILITY WILL THEN EQUITABLY DISTRIBUTE THESE DOSES TO HELP PROTECT THE MOST AT-RISK GROUPS IN ALL PARTICIPATING COUNTRIES. FORM 990, PART I, LINE 5 PART I, LINE 5 LISTS THE TOTAL NUMBER OF EMPLOYEES WHO RECEIVED THE FORM W-2, AND IT DOES NOT INCLUDE FOREIGN EMPLOYEES IN GENEVA, SWITZERLAND. THE TOTAL NUMBER OF EMPLOYEES INCLUDING THE FOREIGN EMPLOYEES IS 290. FORM 990, PART VI, SECTION A, LINE 4 AT THE 24-25 JUNE 2020 BOARD MEETING, THE BOARD APPROVED A NUMBER OF CLARIFYING AMENDMENTS MADE TO THE GAVI STATUTES WITH PARTICULAR ATTENTION TO (I) ARTICLE 10 APPOINTMENT OF BOARD MEMBERS, (II) ARTICLE 12 ORGANISATION OF THE BOARD, AND (III) FUNCTIONS OF THE BOARD. FURTHERMORE, THE BOARD AGREED TO RETIRE GAVI'S BY-LAWS AND REPLACE IT WITH A SET OF OPERATING PROCEDURES FOR THE BOARD AND BOARD COMMITTEES FALLING UNDER THE PURVIEW OF THE BOARD. THE OPERATING PROCEDURES WHICH HAS BEEN INCORPORATED FROM GAVI'S BY-LAWS AND INCLUDES FURTHER PROVISIONS TO ALIGN WITH CURRENT PRACTICE, PARTICULARLY IN RELATION TO THE FOLLOWING: (I) NOMINATION AND APPOINTMENT OF REPRESENTATIVE BOARD MEMBERS, (II) CHAIR, VICE CHAIR AND CEO, (III) MEETING NOTICES, AGENDAS AND PAPERS, PRESENTERS AND OBSERVERS AND CLOSED SESSIONS, AND (IV) TRANSPARENCY. FORM 990, PART VI, SECTION B, LINE 11B THE OUTSOURCED ACCOUNTANT (OA), IN COLLABORATION WITH THE SENIOR MANAGER OF FINANCIAL REPORTING, GATHERS ALL INFORMATION NEEDED TO PREPARE THE FEDERAL FORM 990 FROM THE RESPECTIVE GAVI DEPARTMENTS. OA THEN PREPARES THE DRAFT FEDERAL FORM 990 AND PROVIDES IT TO THE GAVI HEAD OF FINANCIAL ACCOUNTING AND REPORTING (HFAR) FOR REVIEW. THE HFAR REVIEWS THE DRAFT FEDERAL FORM 990 AND DISCUSSES ANY NECESSARY CHANGES WITH THE OA AND SENIOR MANAGER. THE OA THEN SUBMITS THE DRAFT FEDERAL FORM 990 TO THE TAX FIRM FOR REVIEW AND DISCUSSES ANY NECESSARY UPDATES PROVIDED BY THE TAX FIRM, AFTER WHICH THE DRAFT FEDERAL FORM 990 IS UPDATED BY THE OA. THE SENIOR MANAGER THEN CIRCULATES THE UPDATED DRAFT FEDERAL FORM 990 TO VARIOUS GAVI TEAMS FOR THEIR REVIEW AND COMMENT. THE DRAFT FEDERAL FORM 990 IS UPDATED FOR COMMENTS RECEIVED AS DEEMED NECESSARY BY THE HFAR. THE DRAFT FEDERAL FORM 990, INCLUDING ALL REQUIRED SCHEDULES, IS PROVIDED TO THE AUDIT AND FINANCE COMMITTEE. A GAVI AUTHORIZED REPRESENTATIVE SIGNS THE FEDERAL FORM 990 AFTER WHICH IT IS FILED WITH THE INTERNAL REVENUE SERVICE. FORM 990, PART VI, SECTION B, LINE 12C THE GOVERNANCE TEAM CIRCULATES THE CONFLICT OF INTEREST DISCLOSURE FORMS TO THE BOARD MEMBERS ANNUALLY. GOVERNANCE MONITORS DISCLOSURE FORMS BY COLLECTING ALL CONFLICT OF INTEREST DISCLOSURES FROM BOARD MEMBERS. THE POLICY IS MONITORED BY THE BOARD OF DIRECTORS ITSELF, AND RELEVANT CONFLICTS ARE DISCLOSED AT THE BOARD OF DIRECTORS MEETINGS AND NOTED IN THE MINUTES. A BOARD MEMBER/ALTERNATE BOARD MEMBER OR COMMITTEE DELEGATE IS EXPECTED TO DISCLOSE ANY REAL/PERCEIVED OR POTENTIAL CONFLICT TO THE CHAIR OF THE BOARD OR THE COMMITTEE, AS SOON AS POSSIBLE UPON LEARNING OF IT AND NO LATER THAN AT THE BEGINNING OF THE DISCUSSION OF THE PERTINENT AGENDA ITEM DURING A BOARD/COMMITTEE MEETING. IT IS THE PREROGATIVE OF THE CHAIR OF THE MEETING, IN CONSULTATION WITH THE DIRECTOR OF LEGAL OR GOVERNANCE, TO DETERMINE THE SCOPE AND LEVEL OF A CONFLICTED PERSON'S PARTICIPATION IN THE DISCUSSION AND THE NECESSITY OF RECUSAL FROM VOTING GIVEN THE TYPE OF INTEREST DISCLOSED. THE MINUTES OF THE MEETING REFLECT THE CONFLICTED MEMBER'S DISCLOSURE AND WHETHER THE CONFLICTED MEMBER PARTICIPATED IN THE DISCUSSION AND/OR ABSTAINED FROM VOTING. FORM 990, PART VI, SECTION B, LINE 15 GAVI'S COMPENSATION AIMS TO ATTRACT, ENGAGE, REWARD AND RETAIN A TEAM OF HIGH PERFORMING EMPLOYEES WHO ARE DEDICATED TO GAVI'S MISSION. IN 2008, THE GAVI BOARD APPROVED GAVI'S COMPENSATION AND BENEFIT FRAMEWORK. A REVIEW OF THE GAVI SALARY SCALE WAS CONDUCTED IN 2013-2014 BY MERCER, AN INDEPENDENT GLOBAL FIRM SPECIALIZED IN THE FIELD OF COMPENSATION, AND BENCHMARKED AGAINST A COMPOSITE PEER MARKET. THE REVIEW CONCLUDED THAT GAVI'S SALARY SCALE POSITIONING WAS IN ALIGNMENT WITH MARKET AND PEERS. IN 2018, A FURTHER REVIEW WAS UNDERTAKEN BY MERCER. GAVI'S SALARY SCALE HAS NOT CHANGED SINCE ITS INTRODUCTION IN 2008. UPON HIRING, OFFICERS AND KEY EMPLOYEES AT GAVI ARE PLACED WITHIN THE SCALE. FORM 990, PART VI, SECTION C, LINE 19 GOVERNANCE DOCUMENTS AND CONFLICT OF INTEREST POLICY ARE POSTED ON THE GAVI ALLIANCE WEBSITE. FORM 1023 AND FEDERAL FORM 990 ARE MADE AVAILABLE FOR PUBLIC INSPECTION UPON REQUEST. FORM 990, PART VII, SECTION A AN ALTERNATE MEMBER CAN VOTE ONLY WHEN THE CORRESPONDING PRIMARY BOARD MEMBER IS UNABLE TO PARTICIPATE IN VOTING. IF THE PRIMARY BOARD MEMBER IS ABLE TO SUBMIT HIS/HER VOTE THEN THE ALTERNATE MEMBER'S VOTE IS NOT REQUIRED. PART VII LISTS 46 VOTING BOARD MEMBERS. HOWEVER ONLY 27 VOTES COULD BE CAST WHICH ARE PRINCIPAL BOARD MEMBERS. THE 19 ALTERNATE BOARD MEMBERS COULD NOT VOTE UNLESS THEIR ASSOCIATED PRINCIPAL BOARD MEMBER WAS UNAVAILABLE TO VOTE. NONE OF THE ALTERNATE BOARD MEMBER SEATS WERE VACANT. FORM 990, PART XI, LINE 9: RETURN OF UNSPENT FUNDS 991,430. RECOVERY OF PRIOR YEAR GRANT 9,226,447. REVERSAL OF PROVISIONAL CONTRIBUTIONS RECEIVABLE 6,000,000. INTERNATIONAL FINANCE FACILITY FOR IMMUNISATION COMPANY 2 LAMBS PASSAGE LONDON EC1Y 8BB LONDON UK RAISES FUNDS FOR IMMUNIZATION PROGRAMS AND PROCUREMENT UK 501(C)(3) FOREIGN CHARITY GAVI ALLIANCE 1 IFFIM SUKUK COMPANY III LIMITED PO BOX 1093 QUEENSGATE HOUSE GRAND CAYMAN CJ KY1-1102 ISSUING SUKUK CERTIFICATES IN SUPPORT OF IFFIM'S OPERATIONS CJ INTERNATIONAL FINANCE FACILITY FOR IMMUNISATION COMPANY 1 0 0 1 0 0 0 0 0 0 0 0 0 0 1 1 0 1 0 0 INTERNATIONAL FINANCE FACILITY FOR IMMUNISATION COMPANY C 210364608 COST INTERNATIONAL FINANCE FACILITY FOR IMMUNISATION COMPANY N 165440 FMV INTERNATIONAL FINANCE FACILITY FOR IMMUNISATION COMPANY O 745839 FMV INTERNATIONAL FINANCE FACILITY FOR IMMUNISATION COMPANY Q 269554 FMV